These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 38473386)

  • 1. Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment.
    Gmeiner WH
    Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
    Grothey A; Fakih M; Tabernero J
    Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Ros J; Baraibar I; Sardo E; Mulet N; Salvà F; Argilés G; Martini G; Ciardiello D; Cuadra JL; Tabernero J; Élez E
    Ther Adv Med Oncol; 2021; 13():1758835921992974. PubMed ID: 33747149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
    Pohl M; Schmiegel W
    Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Li ZN; Zhao L; Yu LF; Wei MJ
    Gastroenterol Rep (Oxf); 2020 Jun; 8(3):192-205. PubMed ID: 32665851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer.
    Schrock AB; Lee JK; Sandhu J; Madison R; Cho-Phan C; Snider JW; Castellanos E; Venstrom JM; Fakih M
    Oncologist; 2021 Jun; 26(6):469-475. PubMed ID: 33465286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials.
    Vogel A; Kirstein MM
    Innov Surg Sci; 2018 Jun; 3(2):85-86. PubMed ID: 31579770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
    Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
    Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements Towards Individualizing the Treatment.
    Shuford RA; Cairns AL; Moaven O
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33238500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
    Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
    EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer.
    Pan JH; Zhou H; Zhu SB; Huang JL; Zhao XX; Ding H; Pan YL
    Cancer Manag Res; 2018; 10():2289-2301. PubMed ID: 30122982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
    Guerrero RM; Labajos VA; Ballena SL; Macha CA; Lezama MS; Roman CP; Beltran PM; Torrejon AF
    Ecancermedicalscience; 2022; 16():1489. PubMed ID: 36819812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment pathways and associated costs of metastatic colorectal cancer in Greece.
    Sougklakos I; Athanasiadis E; Boukovinas I; Karamouzis M; Koutras A; Papakotoulas P; Latsou D; Hatzikou M; Stamuli E; Balasopoulos A; Sideris A
    Cost Eff Resour Alloc; 2022 Feb; 20(1):7. PubMed ID: 35164784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis.
    Parisi A; Ghidini M; Giampieri R; Tomasello G; Luciani A; Ferri C; Berardi R; Petrelli F
    Clin Colorectal Cancer; 2022 Sep; 21(3):e162-e170. PubMed ID: 35184993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.
    Giordano G; Parcesepe P; Bruno G; Piscazzi A; Lizzi V; Remo A; Pancione M; D'Andrea MR; De Santis E; Coppola L; Pietrafesa M; Fersini A; Ambrosi A; Landriscina M
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.
    Yaeger R; Cercek A; O'Reilly EM; Reidy DL; Kemeny N; Wolinsky T; Capanu M; Gollub MJ; Rosen N; Berger MF; Lacouture ME; Vakiani E; Saltz LB
    Clin Cancer Res; 2015 Mar; 21(6):1313-20. PubMed ID: 25589621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
    Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
    Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives.
    Mizukami T; Izawa N; Nakajima TE; Sunakawa Y
    Drugs; 2019 Apr; 79(6):633-645. PubMed ID: 30968289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.